drugset / Trial / NCT02780700
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this Phase II study is to assess the efficacy and safety of nintedanib alone or in combination with capecitabine for patients with refractory metastatic colorectal cancer (mCRC) after failure of at least 2 lines of standard treatment
Timeline
- Start
- 2016-07-05
- Primary completion
- 2016-09-09
- Completion
- 2016-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Nintedanib | Small molecule | — | — |